The oncological survival and prognosis of individuals receiving PD-1 inhibitor with and without immunologic cutaneous adverse events.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.06.035
Abstract: BACKGROUND The treatment response to new immunotherapy in advanced melanoma patients remains varied between individuals. Immune related cutaneous side effects may have prognostic value. OBJECTIVE To determine whether developing one or more of the three… read more here.
Keywords: prognosis individuals; cutaneous adverse; least one; adverse events ... See more keywords